Region-specific changes in the immunoreactivity of Atg9A in the central nervous system of SOD1(G93A) transgenic mice

Jae Chul Lee¹,², Soo Young Choe², Choong Ik Cha¹
¹Department of Anatomy, Seoul National University College of Medicine, Seoul, ²Department of Biology, School of Life Sciences, Chungbuk National University, Cheongju, Korea

Abstract: Autophagy is a eukaryotic self-degradation system that plays a pivotal role in the maintenance of cellular homeostasis. Atg9 is the only transmembrane Atg protein required for autophagosome formation. Although the subcellular localization of the Atg9A has been examined, little is known about its precise cell and tissue distribution. In the present study, we used G93A mutation in superoxide dismutase 1 [SOD1(G93A)] mutant transgenic mice as an in vivo model of amyotrophic lateral sclerosis (ALS) and performed immunohistochemical studies to investigate the changes of Atg9A immunoreactivity in the central nervous system of these mice. Atg9A-immunoreactivity was detected in the spinal cord, cerebral cortex, hippocampal formation, thalamus and cerebellum of symptomatic SOD1(G93A) transgenic mice. By contrast, no Atg9A-immunoreactivity were observed in any brain and spinal cord region of wtSOD1, pre-symptomatic and early symptomatic mice, and the number and staining intensity of Atg9A-positive cells did not differ in SOD1(G93A) mice between 8 and 13 weeks of age. These results provide evidence that Atg9A-immunoreactivity were found in the central nervous system of SOD1(G93A) transgenic mice after clinical symptoms, suggesting a possible role in the pathologic process of ALS. However, the mechanisms underlying the increased immunoreactivity for Atg9A and the functional implications require elucidation.

Key words: Amyotrophic lateral sclerosis, SOD1(G93A) transgenic mice, Atg9A, Cerebral cortex, Hippocampus, Thalamus

Received February 10, 2014; Revised March 14, 2014; Accepted April 28, 2014

Introduction

Amyotrophic lateral sclerosis (ALS), commonly known as Lou Gehrig's disease, is a progressive and fatal adult-onset neurodegenerative disease characterized by selective loss of central and peripheral motor neurons (MNs) in the brain and spinal cord [1]. The most common mutations found in familiar ALS (10% of total cases) involve the gene that code for the enzyme copper-zinc superoxide dismutase 1 (SOD1). However, this explains only about 20% of familiar ALS cases and 2% of the sporadic form of this disease. This strongly supports the involvement of several genes and the possible role of environmental factors that may trigger the pathogenic mechanisms in vulnerable individuals [2]. The landmark discovery that transgenic mice or rats overexpressing mutant SOD1 have symptoms that mimic human ALS has contributed significantly to our understanding of human ALS [3-6]. The G93A mutation in SOD1 [SOD1(G93A)] is one of the 150 currently known mutations that cause human ALS. Nevertheless, effective approaches for preventing SOD1	
mutation-mediated MN degeneration remain unknown.

Autophagy is a eukaryotic degradative mechanism which maintains cellular homeostasis in environmental stress [7]. It is generally activated by metabolic stresses including hypoxia, nutrient deprivation, and an increase in proliferation [8]. During this process, bulk cytoplasm is sequestered within double-membrane vesicles called autophagosomes and delivered to the lysosome for subsequent degradation and recycling [9]. Recently, 30 autophagy-related (Atg) genes were identified whose products appear to be related to the autophagy process: these genes were characterized in yeast [10-12]. It was found that the molecular basis of autophagy may well be highly conserved from yeast to humans [13, 14]. For example, rat microtubule-associated protein 1 light chain 3, a mammalian homologue of Atg8 plays a critical role in the formation of autophagosomes [15]. Recently, the study of mice deficient for autophagy-related 5 (Atg5) or autophagy-related 7 (Atg7), specifically in neurons, suggested that the continuous clearance of diffuse cytosolic proteins through basal autophagy is important to prevent the accumulation of abnormal proteins, which can disrupt neural function and ultimately lead to neurodegeneration [16-18]. Atg9 is an integral membrane protein localized in the phagophore/pre-autophagosomal structure (PAS), the origin of the autophagosomal membranes [19-21]. Atg9 is required for both the formation and the expansion of the autophagosomes [22, 23]. The role of Atg9A in the formation of autophagosomes remains to be identified, although subcellular localization of the Atg9A protein is clearly dependent on nutrient availability. Because autophagy is a highly conserved degradation system, it is expected that tissue distribution of Atg expression will be relatively uniform [22].

Despite the significance of Atg9A signaling in pathology, relatively little is yet known about the activation of Atg9A signaling in ALS. Therefore, in the current study, we examined ALS-related changes in the levels of Atg9A immunoreactivity in ALS mice using immunohistochemical studies. For the first time, we have demonstrated significant changes in the levels of Atg9A immunoreactivity in the central nervous system (CNS) using SOD1(G93A) mutant transgenic mice as an in vivo model of ALS.

Materials and Methods

Animals and tissue preparation

Twelve male SOD1(G93A) transgenic and 10 male wild-type (wt) SOD1 transgenic mice developed by Gurney et al. [4] were used for these experiments. They were bred by The Jackson Laboratory (Bar Harbor, ME, USA) under the strain designations B6SJL-TgN (SOD1G93A) 1Gur and B6SJL-TgN (SOD1) 2Gur for mutant transgenic and wtSOD1 transgenic mice, respectively. The B6SJL-TgN (SOD1) 2Gur strain carries the normal allele of the human SOD1 gene, and it has been reported that the SOD1 protein levels are the same as in the transgenic strain carrying the SOD1(G93A) transgene. This strain serves as a control for the B6SJL-TgN (SOD1G93A) 1Gur. Animals were sacrificed at the age of 8 (w), 13 (presymptomatic) and 18 (symptomatic) weeks. Clinical symptoms were manifested in the 18w mutant transgenic mice. The first signs of hind limb paresis appeared at 16–18w in the SOD1(G93A) transgenic mice. When suspended from the tail, these mice did not extend symmetrically both hind limbs, as normal mice do. The weak limb was closer to the body. Subsequently, the weakness of one hind limb progressed to paralysis of this limb, and soon thereafter the other hind limb became paralyzed. At that stage, both hind limbs were dragged as the mouse moved around the cage. From the time when transgenic mice showed motor deficits, nutritional gel was routinely placed in the cages of all transgenic animals for easy access to food and hydration. The mice were weighed weekly with an electronic scale. Because of ethical considerations, transgenic animals were euthanized when they were unable to right themselves within 30 seconds. The animals used in this experiment were treated according to the Principles of Laboratory Animal Care (NIH publication no. 86-23). The mice were perfused transcardially with cold phosphate-buffered saline (0.02 M, pH 7.4) and then with ice-cold 4% paraformaldehyde for 10 minutes at a flow rate of 5–6 ml/min. Brains were immediately removed and sliced into 4–6 mm thick blocks. Spinal cords were also removed and sliced into 4–6 mm thick blocks. Spinal cords were also removed and sliced into the cervical, thoracic, and lumbar segments of 3–10 mm in length. These blocks were immersed in a cold fixative for 12 hours and replaced with 20% sucrose for 1–2 days, followed by 30% sucrose for 1–2 days. After the treatment with sucrose solutions, the tissues were embedded in OCT compound (Sakura Fine Tek Inc., Torrance, CA, USA). Frozen sections were cut at 40 μm in the coronal plane at −20°C.

Immunohistochemistry

Immunohistochemistry was performed using the free-floating method as previously described [24, 25]. Briefly, the
goat anti-Atg9A polyclonal antibody (sc-70141, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) was used as the primary antibody. This antibody was affinity-purified and raised against a peptide that mapped near the amino terminus of the human Atg9A protein. Sections were visualized according to the avidin-biotin complex (ABC) method, using an ABC kit (Vectastain, Vector Laboratories, Burlingame, CA, USA) and developed for peroxidase reactivity using 3,3’-diaminobenzidine (Sigma-Aldrich Co., St. Louis, MO, USA). To observe the stained cells, a microscope (Leica DM4500B, Leica Microsystems, Wetzlar, Germany) with a computer-driven digital camera (DFC320, Leica Microsystems) was used.

**Primary antibody specificity testing**

To confirm the specificity of the primary antibodies, we performed a preadsorption test using the previously mentioned immunohistochemical method. In the preadsorption test, sections that were reacted using the above protocol without the primary antibodies were used as negative controls, while other sections were exposed to the anti-Atg9A antibody that had been preabsorbed with Atg9A antibody (Atg9A: sc-70141, Santa Cruz Biotechnology, Inc.) for 24 hours. Other sections were exposed to the anti-Atg9A antibody as positive controls. Negative control sections (not anti-Atg9A antibody) and samples exposed to the anti-Atg9A antibody that had been preabsorbed with Atg9A antibody did not exhibit immunoreactivity, whereas positive controls showed definitive Atg9A immunoreactivity.

**Statistical analysis**

To determine whether the observed changes in Atg9A immunoreactivity were statistically significant, we randomly selected five areas in each brain and spinal cord region of each wtSOD1 transgenic and SOD1(G93A) transgenic mice and compared the determined mean staining densities using the NIH image program (Scion Image). Mean staining density represented the sum of the gray values of all the pixels in the selected area divided by the number of pixels within the area. The averages of the mean staining densities in various brain and spinal cord regions of each animal were then calculated, and the Mann-Whitney U-test was performed using these averages (\(P<0.05\)) (Table 1).

### Table 1. Changes in mean densities of Atg9A immunoreactivity in the central nervous system of symptomatic SOD1(G93A) transgenic mice

| Area                                | (18w) wtSOD1 | (18w) SOD1(G93A) |
|-------------------------------------|--------------|------------------|
| Cerebral cortex                     |              |                  |
| Somatostriatum area                 | 34.4±3.6     | 67.2±4.1*        |
| Cingulate area                      | 35.3±4.3     | 63.6±4.5*        |
| Insular area                        | 32.9±6.1     | 57.8±3.4*        |
| Somatosensory area                  | 37.4±4.5     | 62.1±5.4*        |
| Auditory area                       | 36.6±4.2     | 68.3±5.1*        |
| Visual area                         | 34.3±4.9     | 66.7±4.9*        |
| Entorhinal area                     | 36.9±6.4     | 68.2±5.2*        |
| Hippocampus                         |              |                  |
| CA1 region                          |              |                  |
| Stratum oriens                     | 33.6±4.1     | 42.1±3.5         |
| Pyramidal cell layer                | 39.6±5.7     | 72.8±5.1*        |
| Stratum radiatum                   | 34.3±3.1     | 41.5±4.3         |
| CA3 region                          |              |                  |
| Stratum oriens                     | 34.7±3.1     | 41.4±3.8         |
| Pyramidal cell layer                | 40.1±5.6     | 79.1±4.6*        |
| Stratum radiatum                   | 34.5±4.6     | 40.7±4.1         |
| Dentate gyrus                      |              |                  |
| Granule cell layer                  | 41.6±3.8     | 81.6±5.2*        |
| Polymorphic layer                   | 32.5±4.1     | 41.8±4.2         |
| Thalamus                            |              |                  |
| Lateral group of the dorsal thalamus|              |                  |
| Lateral posterior n.                | 35.1±3.4     | 50.8±3.4*        |
| Posterior complex                   | 34.4±2.8     | 47.9±3.6         |
| Ventral group of the dorsal thalamus|              |                  |
| Ventral anterior-lateral complex    | 32.4±2.5     | 44.9±3.6         |
| Ventral medial n.                   | 33.6±2.9     | 44.7±4.9         |
| Ventral posterior complex           |              |                  |
| Geniculate group of the dorsal thalamus|          |                  |
| Medial geniculate complex           | 33.2±2.1     | 55.9±4.1*        |
| Lateral geniculate complex          | 37.3±3.3     | 59.1±2.7*        |
| Cerebellar Cortex                   |              |                  |
| Molecular layer                     | 34.5±4.2     | 38.3±2.9         |
| Purkinje cell layer                 | 39.6±3.8     | 71.8±4.8*        |
| Granular layer                      | 40.7±4.6     | 50.9±3.9         |
| Spinal cord                         |              |                  |
| Anterior horn                       | 33.6±5.3     | 74.5±5.6*        |

Mean density is the sum of the gray values of all the pixels in the selection that was divided by the number of pixels within the selection. Values are presented as \(\text{mean}±\text{standard deviation}\). The Mann-Whitney U-test was performed (*\(P<0.05\)).

**Results**

Sections from the brain and spinal cord of wtSOD1 transgenic and presymptomatic SOD1(G93A) transgenic mice exhibited strong levels of Atg9A immunoreactivity at the age of 8 weeks and 13 weeks. No differences were observed in staining intensities between the two groups (data not shown). In symptomatic SOD1(G93A) transgenic mice, increased expression of Atg9A was pronounced in the cerebral cortex, hippocampal formation, thalamus, cerebellum and spinal cord.
In the cerebral cortex of wtSOD1 transgenic mice, cells positively stained for Atg9A were observed in layers II–VI in most cortical regions, including the somatomotor area (Fig. 1A), somatosensory area, auditory area, visual area, entorhinal area, piriform area, and prefrontal area. At a higher magnification, Atg9A-immunoreactive cells in symptomatic SOD1(G93A) transgenic mice illustrated the typical morphology of cell bodies (Fig. 1D), whereas only weakly stained cell bodies were found in wtSOD1 transgenic mice (Fig. 1C). There were more Atg9A positive cells in the same cortical regions in symptomatic SOD1(G93A) transgenic mice (Fig. 1B, D). In hippocampal formation, there were layer-specific alterations in the number and staining intensities of Atg9A-immunoreactive cells (Fig. 2A, C). It was noted that the pyramidal cell layers in the CA1-3 region did not exhibit immunoreactivity for Atg9A in wtSOD1 transgenic mice (Fig. 2A, B, E). In symptomatic SOD1(G93A) transgenic mice, Atg9A immunoreactivity was significantly increased in all three layers of the CA1-3 areas, and the alteration was prominent in the pyramidal cell layers (Fig. 2B, D, F). In the dentate gyrus, Atg9A immunoreactivity was also increased in the granule cell layers in SOD1(G93A) transgenic mice (Fig. 2G, H). In the thalamus of wtSOD1 transgenic mice, unstained cell bodies were observed in the dorsal lateral geniculate nucleus, ventral lateral geniculate nucleus, lateral posterior thalamus nucleus, mediorostral, lateral posterior thalamus nucleus, laterorostral, and intramedullary thalamus area (Fig. 3A, C, E, G), while Atg9A-positive cells were strongly detected in symptomatic SOD1(G93A) transgenic mice (Fig. 3B, D, F, H). In the cerebellar cortex of wtSOD1 transgenic mice, unstained cell bodies were observed in the granular, molecular, and Purkinje cell layers (Fig. 4A), while Atg9A positive cells were strongly detected in the same layers in symptomatic SOD1(G93A) transgenic mice (Fig. 4C). At a higher magnification, Atg9A-immunoreactive cells with large cell bodies were not observed in the granular, molecular, and Purkinje cell layers in wtSOD1 transgenic mice (Fig. 4B). High levels of immunoreactivity were detected in the cell bodies of symptomatic SOD1(G93A) transgenic mice (Fig. 4D). In the spinal cord of wtSOD1 transgenic mice, stained cells were not observed in the lumbar segments (Fig. 5A). However, Atg9A immunoreactivity was significantly increased in symptomatic SOD1(G93A) transgenic mice (Fig. 5B). At a higher magnification, the spinal cord layers, dorsal corticospinal tract and anterior horn did not exhibit Atg9A immunoreactive cells with large cell bodies in wtSOD1 transgenic mice (Fig. 5C). High levels of immunoreactivity were detected in the cell bodies in SOD1(G93A) transgenic mice (Fig. 5D). In the cervical, thoracic, and sacral segments, their distribution patterns were similar to those in the cervical segments.

In the brain and spinal cord areas where Atg9A-immuno-

Fig. 1. Localizations of Atg9A-immunoreactive cells in the cerebral cortex of 18w wtSOD1 transgenic (A, C) and 18w symptomatic SOD1(G93A) transgenic mice (B, D). Panels (C) and (D) are high power views of panels (A) and (B), respectively. In the cerebral cortex of SOD1(G93A) transgenic mice (B, D), intensely stained Atg9A-positive cells are seen in layers II–VI of the parietal association cortex, compared with the same areas in wtSOD1 transgenic mice (A, C). At a higher magnification, Atg9A-immunoreactive cells in symptomatic SOD1(G93A) transgenic mice illustrated the typical morphology of cell bodies (D), whereas weakly stained cell bodies were found in wtSOD1 transgenic mice (C). Scale bars=150 μm (A, B), 30 μm (C, D).
reactive cells were located, ALS-related changes in the expression of Atg9A were analyzed. When the distribution of Atg9A immunoreactivity in symptomatic SOD1(G93A) transgenic mice was compared with that in wtSOD1 transgenic mice, the overall distribution pattern seemed to be preserved in symptomatic SOD1(G93A) transgenic mice. The increased levels of Atg9A immunoreactivity observed in these areas were statistically significant at $P<0.05$ (Table 1).

**Discussion**

The present study demonstrated that, in symptomatic SOD1(G93A) transgenic mice, the distribution patterns and staining density of Atg9A immunoreactivity were significantly increased in several areas, such as the cerebral cortex, hippocampal formation, thalamus, cerebellum and spinal cord. Previously, Atg9A-related brain-specific...
expression was reported to be altered in various regions in the brain and spinal cord in mice [11]. In the current study, more Atg9A-immunoreactive cells were observed in the CNS of symptomatic SOD1(G93A) transgenic mice compared with wtSOD1 mice, and Atg9A-immunoreactive cells exhibited increased levels of immunoreactivity compared to those seen in Atg9A-immunoreactive cells. As previously reported [11], Atg9A expression was ubiquitous and high in CNS tissue, particularly in neurons. Also, Atg9A was detected in part in Purkinje cell bodies and distinctly in axon terminals of the cells. Although the PAS, in which Atg proteins are localized, has been shown in yeast, its existence in...
mammalian cells has not been confirmed. Nevertheless, like the PAS membrane in yeast, identification of the membrane origin of autophagosome formation in mammalian cells is very important. Because the Atg9A protein is the only Atg membrane protein, it has been suggested that the Atg9A protein transports membranes during autophagosome formation. The protein is localized to late endosomes, and it dynamically cycles between these organelles under starvation conditions [23, 26]. In fact, generation of Atg9A-deficient mice has shown that the protein is essential for survival during neonatal starvation [27]. These results indicated that the protein expression of Atg9A in mouse tissues may be
regulated in a posttranslational manner [11]. The protein was localized in lysosomes/late endosomes in Purkinje cells of the mouse cerebellum. Moreover, localization of the Atg9A protein both in the axon terminals of Purkinje and basket cells and in Purkinje cells suggests that the Atg9A protein, which is the only membrane Atg protein, may play an essential role in the initiation of autophagosome formation.

There have been several reports of autophagy in ALS [27-30]. Autophagy in transgenic mice with the G93A mutant SOD1 gene is increased because of upregulation of Atgs immunoreactivity, and mutations in the autophagy-lysosomal pathway transport machinery have been shown to be associated with frontotemporal dementia and ALS [31-33]. A detectable, although variable in magnitude, degree of cognitive involvement has been found in many patients with ALS. Indeed, 5–15% of ALS patients meet criteria for frontotemporal dementia, while a substantial percentage of patients without dementia may show mild to moderate executive (approximately from 22% to 35%) and behavioral (up to 63%) dysfunctions [7-9]. Structural and functional magnetic resonance imaging, positron emission tomography, and single photon emission-computed tomography studies have corroborated the theory of frontotemporal impairment in ALS with approximately half of the patients displaying at least mild abnormalities [34-37]. Moreover, by electron microscopy, all ALS patients exhibited autophagosomes and/or autolysosomes in the cytoplasm of both normal-appearing and, more frequently, degenerated MNs, and an increase in autophagic processes was closely correlated with ALS-characteristic inclusions. In this regard, it is possible that the autophagic pathway could be preferentially activated in the cellular response to misfolded proteins in the endoplasmic reticulum (ER), because ER stress seems to be involved in the pathomechanism of neurodegeneration of MNs in sporadic ALS [38, 39]. The absence of autophagosomes in the cytoplasm of normal-looking MNs in controls is consistent with previous reports that have shown that the levels of autophagosomes detected in neurons are very low under normal and even starvation conditions [40]. By contrast, both autophagosomes and autolysosomes were far more abundant in the cytoplasm of MNs in patients with sporadic ALS, which is consistent with typical results of induction of autophagy [41].

Previously, To test new therapies, investigators measured clinical, histological and functional features so as to be able to evaluate disease severity and progression in SOD1 mice. They compared six testing methods including clinical grading, weighing, hanging wire test, rotarod test, MN counting and motor unit number estimation in SOD1 mice and control animals. The number of functional motor units precisely correlated with MN counts [42]. A confirmed relation between autophagy and ALS exits, but it is still controversial whether activating autophagy is beneficial or detrimental for the MNs degeneration. Autophagy is considered as initial factor to ALS process, but expanding evidence suggests the impaired autophagic flux and excessive autophagic vacuoles are responsible for this pathologic alternation in late stage. ALS-associated protein aggregations and certain mutant genes may be possible causative factors for autophagic flux inhibition. Further studies need to be done to elucidate other molecules and possible mechanisms involved in ALS, which can help us depict a more integrated network between autophagy and ALS [43].

As shown in the present study, the levels of Atg9A immunoreactivity were increased in several brain and spinal cord of the symptomatic SOD1(G93A) transgenic mice, suggesting that the levels of expression of Atg9A is altered in specific brain and spinal cord areas during ALS development, and these changes may provoke specific functional consequences. We have demonstrated, for the first time, that Atg9A immunoreactivity was significantly increased in the cerebral cortex, hippocampal formation, thalamus and spinal cord of the CNS of SOD1(G93A) transgenic mice. These results propose that changes in expression levels of Atg9A may underlie several ALS-induced selective neuronal losses in symptomatic SOD1(G93A) transgenic mice. Controlling the activity of these proteins has become a specific target in the treatment of motor functional deficits in degenerative and neurological diseases. However, more work into understanding the function and role of Atg9A signaling is still required. Thus, the functional consequences of Atg9A signaling have yet to be elucidated.

**Acknowledgements**

This work was supported by grant no. 04-2012-0470 from the SNUH Research Fund and the Korea Foundation for the Advancement of Science and Creativity (KOFAC) grant funded by the Korea government (MEST).

**References**

1. Cleveland DW, Rothstein JD. From Charcot to Lou Gehrig:
deciphering selective motor neuron death in ALS. Nat Rev Neurosci 2001;2:806-19.
2. Venerosi A, Martire A, Rungi A, Pieri M, Ferrante A, Zona C, Popoli P, Calamandrei G. Complex behavioral and synaptic effects of dietary branched chain amino acids in a mouse model of amyotrophic lateral sclerosis. Mol Nutr Food Res 2011;55:541-52.
3. Brujin Li, Housewear MK, Kato S, Anderson KL, Anderson SD, Ohama E, Reaume AG, Scott RW, Cleveland DW. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science 1998;281:1851-4.
4. Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, Caliendo J, Hentati A, Kwon YW, Deng HX, Chen W, Zhai P, Sufit RL, Siddique T. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 1994;264:1772-5.
5. Nagai M, Aoki M, Miyoshi I, Kato M, Pasinelli P, Kasai N, Brown RH Jr, Ityoama Y. Rats expressing human cytosolic copper-zinc superoxide dismutase transgenes with amyotrophic lateral sclerosis: associated mutations develop motor neuron disease. J Neurosci 2001;21:9246-54.
6. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, Donaldson D, Goto J, O’Regan JP, Deng HX, Rahmani Z, Križus A, Mckenna-Yasek D, Kayabay A, Gaston SM, Berger R, Tanzi RE, Halperin JJ, Herfeldt B, van den Bergh R, Hung WY, Bird T, Deng G, Mulder DW, Smyth C, Laing NG, Soriano E, Pericak-vance MA, Haines J, Rouleau GA, Gusella JS, Horvitz HR, Brown RH Jr. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993;362:59-62.
7. Murphy J, Henry R, Lomen-Hoerth C. Establishing subtypes of the continuum of frontal lobe impairment in amyotrophic lateral sclerosis: associated mutations develop motor neuron disease. J Neurosci 2001;21:9246-54.
8. Phukan J, Pender NP, Hardiman O. Cognitive impairment in amyotrophic lateral sclerosis. Lancet Neurol 2007;6:994-1003.
9. Ringholz GM, Appel SH, Bradshaw M, Cooke NA, Mosnik DM, Schulze PE. Prevalence and patterns of cognitive impairment in ALS. Neurology 2005;65:586-90.
10. Klionsky DJ, Cregg JM, Dunn WA Jr, Emr SD, Sakai Y, Sandoval IV, Sibirny A, Subramani S, Thumm M, Veenhuis M, Ohsumi Y. A unified nomenclature for yeast autophagy-related genes. Dev Cell 2003;5:539-45.
11. Tamura H, Shibata M, Koike M, Sasaki M, Uchiyama Y. Atg9A protein, an autophagy-related membrane protein, is localized in the neurons of mouse brains. J Histochem Cytochem 2010;58:443-53.
12. Yorimitsu T, Klionsky DJ. Autophagy: molecular machinery for self-eating. Cell Death Differ 2005;12 Suppl 2:1542-52.
13. Levine B, Klionsky DJ. Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev Cell 2004;6:463-77.
14. Reggiori F, Klionsky DJ. Autophagy in the eukaryotic cell. Eukaryot Cell 2002;1:11-21.
15. Kirisako T, Baba M, Ishihara N, Miyazawa K, Ohsumi M, Yoshimori T, Noda T, Ohsumi Y. Formation process of autophagosome is traced with Apg8/Aut7p in yeast. J Cell Biol 1999;147:435-46.
16. Harada T, Nakamura K, Matsu M, Yamamoto A, Nakahara Y, Suzuki-Migishima R, Yokoyama M, Mishima K, Saito I, Okano H, Mizushima N. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature 2006;441:883-9.
17. Komatsu M, Waguri S, Chiba T, Murata S, Iwata J, Tanida I, Ueno T, Koike M, Uchiyama Y, Kominami E, Tanaka K. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature 2006;441:880-4.
18. Rubinsztein DC. The roles of intracellular protein-degradation pathways in neurodegeneration. Nature 2006;443:780-6.
19. Krick R, Muehe Y, Prick T, Bremer S, Schlotterhose P, Eskelinen EL, Millen J, Goldfarb DS, Thumm M. Piecemeal micro-autophagy of the nucleus requires the core macroautophagy genes. Mol Biol Cell 2008;19:4492-505.
20. Sekito K, Kawamata T, Ichikawa R, Suzuki K, Ohsumi Y. Atg17 recruits Atg9 to organize the pre-autophagosomal structure. Genes Cells 2009;14:525-38.
21. Suzuki K, Kirisako T, Kamada Y, Mizushima N, Noda T, Ohsumi Y. The pre-autophagosomal structure organized by concerted functions of APG genes is essential for autophagosome formation. EMBO J 2001;20:5971-81.
22. Yamada T, Carson AR, Canigia I, Umebayashi K, Yoshimori T, Nakabayashi K, Scherer SW. Endothelial nitric-oxide synthase antisense (NOS3AS) gene encodes an autophagy-related protein (APG9-like2) highly expressed in trophoblast. J Biol Chem 2005;280:18283-90.
23. Young AR, Chan EY, Hu XW, Köch R, Crawshaw SG, High S, Hailey DW, Lippincott-Schwartz J, Tooze SA. Starvation and ULK1-dependent cycling of mammalian Atg9 between the TGN and endosomes. J Cell Sci 2006;2011(Pt 18):3888-900.
24. Lee JC, Chung YH, Cho YJ, Kim J, Kim N, Cha CI, Joo KM. Immunohistochemical study on the expression of calcium binding proteins (calbindin-D28k, calretinin, and parvalbumin) in the cerebellum of the nNOS knockout(-/-) mice. Anat Cell Biol 2010;43:64-71.
25. Lee JC, Shin JH, Park BW, Kim GS, Kim JC, Kang KS, Cha CI. Region-specific changes in the immunoreactivity of SIRT1 expression in the central nervous system of SOD1(G93A) transgenic mice as an in vivo model of amyotrophic lateral sclerosis. Brain Res 2012;1433:20-8.
26. Webster JL, Young AR, Tooze SA. Atg9 trafficking in mammalian cells. Autophagy 2007;3:54-6.
27. Aguib Y, Heiseke A, Gilch S, Riemer C, Baier M, Schätzl HM, Ertmer A. Autophagy induction by trehalose counteracts cellular prion infection. Autophagy 2009;5:361-9.
28. Fornai F, Longone P, Caffaro L, Kastsiuchenka O, Ferrucci M, Manca ML, Lazzeri G, Spalloni A, Bellio N, Lenzi P, Modugno N, Siciliano G, Isidoro C, Murri L, Ruggieri S, Paparelli A. Lithium delays progression of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 2008;105:2052-7.
29. Sasaki S. Autophagy in spinal cord motor neurons in sporadic amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 2011;70:349-59.
30. Webb JL, Ravikumar B, Atkins J, Skepper JN, Rubinsztein DC. Alpha-Synuclein is degraded by both autophagy and the proteasome. J Biol Chem 2003;278:25009-13.
31. Li L, Zhang X, Le W. Altered macroautophagy in the spinal cord of SOD1 mutant mice. Autophagy 2008;4:290-3.
32. Morimoto N, Nagai M, Ohta Y, Miyazaki K, Kurata T, Morimoto M, Murakami T, Takehisa Y, Ikeda Y, Kamiya T, Abe K. Increased autophagy in transgenic mice with a G93A mutant SOD1 gene. Brain Res 2007;1167:112-7.
33. Rusten TE, Simonsen A. ESCRT functions in autophagy and associated disease. Cell Cycle 2008;7:1166-72.
34. Agosta F, Pagani E, Rocca MA, Caputo D, Perini M, Salvi F, Prelle A, Filippi M. Voxel-based morphometry study of brain volumetry and diffusivity in amyotrophic lateral sclerosis patients with mild disability. Hum Brain Mapp 2007;28:1430-8.
35. Kew JJ, Goldstein LH, Leigh PN, Abrahams S, Cosgrave N, Passingham RE, Frackowiak RS, Brooks DJ. The relationship between abnormalities of cognitive function and cerebral activation in amyotrophic lateral sclerosis. A neuropsychological and positron emission tomography study. Brain 1993;116(Pt 6):1399-423.
36. Rose S, Pannek K, Bell C, Baumann F, Hutchinson N, Coulthard A, McCombe P, Henderson R. Direct evidence of intra- and interhemispheric corticomotor network degeneration in amyotrophic lateral sclerosis: an automated MRI structural connectivity study. Neuroimage 2012;59:2661-9.
37. Vercelletto M, Ronin M, Huvet M, Magne C, Feve JR. Frontal type dementia preceding amyotrophic lateral sclerosis: a neuropsychological and SPECT study of five clinical cases. Eur J Neurol 1999;6:295-9.
38. Nagata T, Ilieva H, Murakami T, Shiote M, Narai H, Ohta Y, Hayashi T, Shoji M, Abe K. Increased ER stress during motor neuron degeneration in a transgenic mouse model of amyotrophic lateral sclerosis. Neuror Res 2007;29:767-71.
39. Sasaki S. Endoplasmic reticulum stress in motor neurons of the spinal cord in sporadic amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 2010;69:346-55.
40. Mizushima N. Autophagy: process and function. Genes Dev 2007;21:2861-73.
41. Mizushima N, Yoshimori T, Levine B. Methods in mammalian autophagy research. Cell 2010;140:313-26.
42. Zhou C, Zhao CP, Zhang C, Wu GY, Xiong F, Zhang C. A method comparison in monitoring disease progression of G93A mouse model of ALS. Amyotroph Lateral Scler 2007;8:366-72.
43. Song CY, Guo JF, Liu Y, Tang BS. Autophagy and Its Comprehensive Impact on ALS. Int J Neurosci 2012;122:695-703.